GIP Products for Obesity and Diabetes Research

GIPR MOA-reflective Assays to Advance Next-generation Therapeutics Development for Obesity and Diabetes

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted in response to nutrient intake, acting through the GIP receptor (GIPR) to regulate insulin secretion, lipid metabolism, and energy balance. Although GIPR agonists alone have demonstrated limited effectiveness in treating type 2 diabetes, they have become increasingly important as part of dual and triple incretin strategies. In these contexts, GIPR activation complements GLP-1R and other pathways, enhancing glycemic control and weight management in obesity and diabetes therapies.

To support these therapeutic advances, Eurofins DiscoverX® provides a comprehensive set of tools to study GIPR signaling and function. The portfolio offers human and ortholog cell line assays, and quick-analysis ready-to-assay eXpress assay kits to investigate pharmacological characterization, signaling pathways, and ligand bias. Additionally, phase-appropriate qualified bioassays for both tirzepatide and GIP receptor agonists (GIP-RAs) enable the acceleration of drug development programs via regulatory-aligned potency and stability testing.

Together, these solutions provide mechanism of action (MOA)-reflective data that accelerate drug discovery and development efforts targeting GIPR, whether pursued as monotherapies or as part of combination incretin approaches.

Product Highlights
  • Comprehensive GIPR Assay Portfolio – Human and ortholog cell lines, eXpress kits, qualified bioassays, and detection reagents covering every stage of drug discovery and development
  • Multiple MOA Formats – Measure ligand activity across cAMP signaling, β-arrestin recruitment, and receptor internalization for a complete pharmacological profile
  • Regulatory-ready Solutions – Qualified bioassays for potency and bio-identity testing, widely cited in publications, patents, and regulatory submissions
  • Designed for Evolving Therapies – Supports GIPR multi-target incretin programs

Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.

SHOP PRODUCTSREAD APP NOTEVIEW WEBINARREVIEW POSTERSEE PRESENTATION

Products

Eurofins DiscoverX provides a full suite of GIP tools to support drug discovery including human and ortholog cell lines, ready-to-use eXpress assay kits, membrane preparations, and qualified and target-based bioassays for potency and regulatory-compliant testing.
 

Product Types

  • GIP Bioassays Kits - Ready-to-use cell-based assay kits with a simple, homogeneous protocol. These physiologically relevant, robust bioassays are fit-for-purpose for use in screening and characterization applications as well as potency testing in quality control lot-release programs.
  • GIP Stable Cell Lines - Stable cell lines (continuous culture) developed to reflect the target’s mechanism of action (cAMP and β-arrestin) with a drugs’ interaction in a standard cell line background.
  • GIP eXpress Assay Kits - Ready-to-use cell-based assay kits for quick analysis and implementation in early discovery phases for screening applications, proof-of-concept, MOA confirmation (cAMP and β-arrestin), and rank-ordering studies.
  • GIP Membrane Preparations - Derived from proprietary stable recombinant cells to ensure high levels of receptor surface expression. Ideal for screening ligand binding affinities.

 

Applications